Clinical and Experimental Dermatology最新文献

{"title":"A mimicker of melanoma on sun-exposed sites.","authors":"Paula Finnegan, Clara Lightner, James Clover, Cynthia Heffron, Catherine Quinlan","doi":"10.1093/ced/llaf199","DOIUrl":"10.1093/ced/llaf199","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2085-2088"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort.","authors":"Oras A Alabas, Ian Evans, Kathleen Mcelhone, Zenas Z N Yiu, Nick J Reynolds, Philip Laws, Anthony Bewley, Catherine H Smith, Mark Lunt, Christopher E M Griffiths, Richard B Warren","doi":"10.1093/ced/llaf224","DOIUrl":"10.1093/ced/llaf224","url":null,"abstract":"<p><strong>Background: </strong>Since the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) was established in 2007, numerous biologic therapies have been introduced for the better management of psoriasis.</p><p><strong>Objectives: </strong>To describe baseline demographics, disease characteristics and real-world biologic utilization in patients entering BADBIR over time.</p><p><strong>Methods: </strong>Patients with moderate-to-severe psoriasis registered in BADBIR between 2007 and 2024 were included. Percentages were used to describe categorical variables and the median with interquartile range (IQR) for continuous variables. The year of enrolment was divided into Early (2007-2014) and Late (2015-2024) periods.</p><p><strong>Results: </strong>As of April 2024, there were 21 407 registrations in BADBIR. Compared with the Early period, more minority ethnic groups [1374/11 383 (12.1%) vs. 868/10 024 (8.7%)] were enrolled in the Late period. Shorter disease duration [median years, 18 (IQR 10-28) vs. 20 (11-29)], lower severity measured using Psoriasis Area and Severity Index [median 11 (IQR 6-16) vs. 14 (IQR 10-19)] and fewer patients with comorbidities [6298/11 383 (55.3%) vs. 5905/10 024 (58.9%)] were reported in the Late vs. the Early period. There were 6236 (29.1%) patients in the conventional cohort and 15 171 (70.9%) in the biologic cohort from 2007 to 2024 (total N = 21 407). Out of 15 171 individuals in the biologic cohort, 8299 (54.7%), 3227 (21.3%) and 1170 (7.7%) switched to second, third and fourth lines of therapy, respectively. In 15 171 individuals (2007-2024), adalimumab was the most frequently prescribed first-line therapy, followed by ustekinumab and etanercept [6576 (43.4%), 3349 (22.1%) and 1750 (11.5%), respectively]. Despite the significant drop in utilization over time, adalimumab remained the most frequent first-line biologic in the Late period 3092/8716 (35.5%), followed by ustekinumab 2087/8716 (23.9%) and secukinumab 1445/8716 (16.6%). However, utilization of biologics in the subsequent lines of therapies has changed over time in newer biologics, with mainly guselkumab and risankizumab becoming the most frequent in recent years.</p><p><strong>Conclusions: </strong>Patients registered in the Late period have less severe psoriasis, shorter disease duration and fewer comorbidities than those enrolled in the Early period. The most frequent biologics at enrolment were adalimumab and ustekinumab; however, this has changed with the introduction of new and more effective biologics. BADBIR is a rich data source providing information on the management of psoriasis.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1995-2006"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum raftlin and 8-isoprostaglandin F2α as potential biomarkers in seborrhoeic dermatitis: a case-control study.","authors":"Mehmet Enes Güner, Ergül Belge Kurutaş, Perihan Öztürk","doi":"10.1093/ced/llaf243","DOIUrl":"10.1093/ced/llaf243","url":null,"abstract":"<p><strong>Background: </strong>Seborrhoeic dermatitis (SD) is a chronic inflammatory skin disorder associated with Malassezia species, immune dysregulation and potential oxidative stress. While previous studies have explored general inflammatory and oxidative mechanisms, specific biomarkers such as raftlin and 8-isoprostaglandin F2α (8-iso-PGF2α) have not yet been investigated in SD.</p><p><strong>Objectives: </strong>To evaluate serum raftlin and 8-iso-PGF2α levels in patients with SD and to determine their relationship with disease severity.</p><p><strong>Methods: </strong>This cross-sectional study included 50 patients with SD and 50 age- and sex-matched healthy controls. Disease severity was assessed using the Seborrheic Dermatitis Area and Severity Index. Serum raftlin and 8-iso-PGF2α levels were measured via the enzyme-linked immunosorbent assay. Statistical analyses included independent-samples t-tests, Spearman correlation and receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>Both raftlin and 8-iso-PGF2α levels were significantly higher in patients with SD than in controls (P < 0.001 for both). ROC analysis showed strong discriminatory performance for raftlin (area under the curve 0.987; cutoff 9.30 ng mL-1, 92% sensitivity, 100% specificity) and perfect accuracy for 8-iso-PGF2α (area under the curve 1.000; cutoff 27.9 pg mL-1, 100% sensitivity and specificity). No significant correlation was found between biomarker levels and disease severity.</p><p><strong>Conclusions: </strong>This study demonstrated that serum raftlin and 8-iso-PGF2α levels are significantly elevated in patients with seborrhoeic dermatitis compared with healthy controls. ROC curve analysis indicated strong discriminatory capacity, particularly for 8-iso-PGF2α, which achieved perfect sensitivity and specificity in this cohort. While these biomarkers are not specific to SD and reflect broader inflammatory and oxidative mechanisms, their strong discriminatory ability supports their potential role as adjunctive diagnostic indicators in clinical or research settings. Further validation in larger, multicentre cohorts is warranted to assess their utility across diverse populations and comorbid conditions.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1989-1994"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finasteride use and suicide attempts through self-poisoning: a case-control study.","authors":"Ida M Heerfordt, Annika Magdalena Rhomberg-Kauert, Kim Peder Dalhoff, Morten Tulstrup, Henrik Horwitz","doi":"10.1093/ced/llaf268","DOIUrl":"10.1093/ced/llaf268","url":null,"abstract":"<p><p>This study investigated the potential link between finasteride, commonly used for hair loss, and suicide attempts via self-poisoning. It was -motivated by concerns over unanticipated psychological side-effects like suicidality identified in post-trial adverse event reports. We used data from multiple Danish health registries to assess male patients reported for suicidal intent poisoning. Each case was matched with 10 controls based on age, sex and residential municipality. We collected data on finasteride prescriptions up to 1 year before the index date, which was the date of the suicide attempt for cases and the inclusion date for controls. The study included 3366 cases and 33 660 controls. Adjustments were made for diagnosed bipolar disorder and schizophrenia, as well as occupational status. The analysis showed no link between finasteride use and suicide attempt risk, with an unadjusted odds ratio of 1.03 (95% confidence interval 0.56-1.88) and an adjusted odds ratio of 0.88 (95% confidence interval 0.45-1.71).</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2037-2039"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itchy bruising in a 5-year-old girl.","authors":"Xi Tan, Zhouwei Wu","doi":"10.1093/ced/llaf237","DOIUrl":"10.1093/ced/llaf237","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2093-2095"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"True malignant transformation in a proliferating trichilemmal tumour.","authors":"Saerrah Murryam, Sian Hughes, Eduardo Calonje, Christopher Bunker","doi":"10.1093/ced/llaf247","DOIUrl":"10.1093/ced/llaf247","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2060-2061"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome and pigmentation: a review of the connecting link.","authors":"Abheek Sil, Shreya Poddar, Anupam Das, Diptarup Ray","doi":"10.1093/ced/llaf218","DOIUrl":"10.1093/ced/llaf218","url":null,"abstract":"<p><p>There is an ongoing interest regarding the association of metabolic syndrome (MetS) and skin diseases. However, the link between MetS and pigmentation has not been extensively explored. In this review, we undertake a detailed discussion on the existing literature on this topic, the various implicated pathomechanisms and/or molecular pathways, and highlight scope for further scientific exploration. A better understanding of the relationship between MetS and disorders of pigmentation contributes to early diagnosis and prevention, as well as providing clues for developing novel therapeutic strategies.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1953-1962"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol-induced facial erythema in patients treated with dupilumab: a case series and systematic review.","authors":"Amit Iton-Schwartz, Rivka Friedland, Daniel Mimouni, Yael A Leshem","doi":"10.1093/ced/llaf206","DOIUrl":"10.1093/ced/llaf206","url":null,"abstract":"<p><strong>Background: </strong>Dupilumab-associated head and neck dermatitis in patients with atopic dermatitis has been extensively documented. A distinctive short-lived facial erythema after alcohol ingestion in patients treated with dupilumab has recently emerged.</p><p><strong>Objectives: </strong>To characterize alcohol-induced facial erythema on treatment with dupilumab.</p><p><strong>Methods: </strong>We conducted a systematic review based on PubMed and Google Scholar searches for publications on alcohol-induced facial erythema on treatment with dupilumab. A case series from our centre was added to this review. Data were summarized using descriptive statistics and a narrative review. This systematic review adhered to PRISMA reporting guidelines and was registered with PROSPERO (CRD42024571723).</p><p><strong>Results: </strong>Seven publications describing nine patients and five more from our case series were included. All were adults treated for atopic dermatitis (nine males; mean age 32.4 years, SD 9.8). Six patients applied concomitant topical calcineurin inhibitors. At a median of 26 weeks (range 3 weeks to 3 years) from dupilumab initiation, patients exhibited facial erythema/flushing within minutes of alcohol consumption, resolving spontaneously in an hour. No patient discontinued dupilumab. One patient reported initial successful prophylaxis with a histamine H2-receptor antagonist.</p><p><strong>Conclusions: </strong>Alcohol-induced facial erythema/flushing on dupilumab has only been described in atopic dermatitis and is characterized by an acute onset and rapid resolution. Topical calcineurin inhibitor applications did not account for most patients' cases. Although seemingly an uncommon phenomenon, its social media presence suggests that it is underreported and troublesome to patients.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1975-1981"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare ocular manifestation of discoid lupus: diagnostic and therapeutic considerations.","authors":"Dhanya Kuladeva, Puo Nen Lim, Hazel Rooney, Laura Dunbar, Catherine Jury","doi":"10.1093/ced/llaf229","DOIUrl":"10.1093/ced/llaf229","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2046-2048"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetics and general dermatology.","authors":"Mohammed Abbasi, Prajwal Pudasaini, Faisal Dubash","doi":"10.1093/ced/llaf270","DOIUrl":"10.1093/ced/llaf270","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2082-2084"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}